IRadimed spent its last earnings call making a case that flat revenue was hiding a business on the verge of acceleration. Its new 3870 MRI-compatible infusion pump was off to a faster start than planned, bookings were running at more than twice shipments, and customers were buying pricier configurations than anyone expected. The third-quarter report is where that story has to show up in the numbers, because management has effectively promised a steep production ramp, a sequential revenue jump and the start of a margin recovery all at once.

The Street is looking for earnings of $0.52 per share, roughly 21% above the $0.43 earned a year ago. That is solid growth, but the more telling comparison is with management's own outlook. The company guided to non-GAAP earnings of $0.54 to $0.59 on revenue of $23.0 million to $24.5 million, and it reaffirmed full-year targets of $91 million to $96 million in revenue for the third consecutive call. The current consensus sits slightly below the bottom of that non-GAAP range, though the two figures may not be calculated on the same basis. Either way, analysts are not leaning on the optimistic end of management's framework. The revenue guide itself is demanding: hitting even the low end requires a sequential jump of about $2.5 million from the $20.5 million reported last quarter, and growth of roughly 8% to 16% over the year-ago $21.2 million.

The central operating question is whether IRadimed actually built and shipped more than 300 pumps, the raised target it set after producing just over 130 in the second quarter from a standing start. More than doubling output in a single quarter is no small feat for a company still climbing a manufacturing learning curve. Those inefficiencies pushed gross margin down to 74% from 78% a year earlier, below its historical 75% to 77% band. If volumes ramped as planned, fixed labor and overhead should spread across far more units, and margin should begin moving back toward historical levels. A quarter in which revenue rises but margin stays stuck near 74% would raise uncomfortable questions about how quickly the factory can absorb demand, especially with management signaling that a fourth quarter running at a $100 million annual pace is within reach and could carry record margins.

Pricing and mix provide the other half of the bull case. Management raised its average selling price expectations repeatedly, from a 10% to 14% premium over the legacy 3860 initially to more than 20% now, with four-channel quad systems topping $110,000 and accounting for roughly 70% of replacements. Confirmation that this mix held up as volumes scaled would be meaningful evidence that the upgrade cycle is richer than originally modeled. Investors should also check whether legacy 3860 declines are fading, whether disposables and monitors keep their double-digit momentum, and whether lead times, already stretching to four to six months or more, are a sign of healthy backlog or a bottleneck. A tax rate near 24%, up from earlier hopes of about 21%, will also shave a bit off reported earnings.

The market has grown skeptical. Shares have fallen about 10% since the last report while the S&P 500 gained nearly 3%, and at $87.64 the stock trades below its 200-day moving average of $93.04, in the lower half of its post-earnings range between $81.41 and $97.74. Sentiment has swung from mildly bullish heading into the prior report to deeply bearish now. That pessimism lowers the bar somewhat, but it also suggests investors want proof rather than promises.

Ultimately, this report comes down to whether the 3870 ramp converts into simultaneous revenue growth and margin repair. Shipping more than 300 units with gross margin heading back toward the mid-70s would validate management's acceleration narrative and make the $100 million run rate look credible. A shortfall in production or a margin that refuses to budge would suggest the transition trough is deeper and longer than promised.